Low Dose Naltrexone for Autoimmune Disease (2026)

Low dose naltrexone (LDN) is one of the most compelling and underutilized treatments in autoimmune medicine. At 1.5 to 4.5mg nightly (roughly one-tenth the standard addiction-treatment dose), naltrexone shifts from opioid blocker to immune modulator, producing anti-inflammatory effects through two well-characterized mechanisms. Clinical trial evidence exists for Crohn's disease, fibromyalgia, multiple sclerosis, and several other autoimmune conditions. LDN is off-label, inexpensive, generally well-tolerated, and compatible with most conventional autoimmune medications. It requires a physician prescription and compounding pharmacy. This guide covers the mechanism, evidence by condition, dosing protocol, how to obtain it, and what to expect. Discuss LDN with your physician before starting.

What Is Low Dose Naltrexone?

Naltrexone was FDA-approved in 1984 as an opioid antagonist. At its standard dose of 50mg per day, it blocks opioid receptors continuously. This continuous blockade is the mechanism behind its use in opioid and alcohol use disorder.

In the late 1980s, Bernard Bihari, a New York physician, observed that HIV patients taking low doses of naltrexone at bedtime showed unexpected improvements in immune function. His hypothesis: brief, partial opioid receptor blockade followed by rebound upregulation of endogenous opioid production, with downstream immune-modulating effects.

The term "low dose naltrexone" was coined to describe doses between 1 and 5mg, a range where the drug behaves fundamentally differently from its standard application. At these doses, receptor blockade is transient (4-6 hours) rather than continuous. This transience is not a limitation. It is the mechanism.

Since Bihari's early observations, two distinct biological mechanisms at low doses have been characterized:

How LDN Works: Two Mechanisms

Mechanism 1: TLR4 Antagonism (The Anti-Inflammatory Pathway)

Toll-like receptor 4 (TLR4) is a pattern recognition receptor expressed on microglia, macrophages, and other immune cells. TLR4 is the receptor for lipopolysaccharide (LPS), the bacterial cell wall component that triggers systemic inflammatory cascades. When TLR4 is activated, it drives NF-κB signaling → pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6, IL-17).

Naltrexone, at low doses, blocks TLR4 directly. Critically, this TLR4-blocking effect is opioid-receptor independent. Work by Hutchinson et al. (2008, 2010) demonstrated that the (+)-isomer of naltrexone (which does not bind opioid receptors) retains TLR4-blocking activity equal to the standard (-)-isomer. This means naltrexone has a direct anti-inflammatory mechanism at TLR4 that operates regardless of opioid signaling.

The clinical implication: in conditions where TLR4-driven neuroinflammation or systemic inflammation is a driver (including Hashimoto's, Crohn's, MS, and RA), LDN's TLR4 antagonism reduces the inflammatory cytokine milieu that perpetuates autoimmune tissue damage.

This mechanism is active continuously at low doses, not just during the transient opioid blockade window.

Mechanism 2: The OGF Rebound (The Immune-Modulating Pathway)

The opioid growth factor (OGF) system is distinct from the pain-mediating opioid pathways most people associate with naltrexone. OGF is met-enkephalin (an endogenous opioid peptide) that binds the OGF receptor (OGFr, also called the zeta receptor) found on lymphocytes, natural killer cells, and regulatory T cells.

The OGF-OGFr axis acts as a constitutive brake on immune cell proliferation. When OGF binds OGFr, it inhibits cell cycling, reducing the rate at which immune cells divide and accumulate. In autoimmune disease, where autoreactive lymphocytes are overproliferating, OGF pathway enhancement would theoretically reduce the autoreactive population.

Here is where LDN's timing becomes critical:

Endogenous opioid (endorphin) production peaks between 2:00 and 4:00 AM. When LDN is taken at bedtime, peak plasma naltrexone levels coincide with this peak endorphin window. Naltrexone transiently blocks OGF receptors during this 2-4 hour period. The body's response to this blockade: upregulation of OGF production and OGFr sensitivity (receptor upregulation).

When the naltrexone clears (4-6 hours later), the system rebounds with enhanced OGF signaling: more OGF, more sensitive receptors, stronger constitutive brake on immune cell proliferation. The net result across months of nightly LDN: modulated (not suppressed) immune activity with reduced autoreactive lymphocyte proliferation.

This is why taking LDN in the morning reduces efficacy. You miss the 2-4am peak endorphin window that is the therapeutic target for the OGF rebound mechanism.

What LDN Is Not

LDN is not an immunosuppressant. It does not work like methotrexate, biologics (TNF inhibitors, IL-17 blockers), or corticosteroids. It does not broadly suppress immune function.

This distinction matters clinically: LDN does not appear to increase infection risk, a critical advantage for long-term autoimmune management where immunosuppression-related infections are a major safety concern with conventional therapies.

LDN appears to modulate immune function rather than suppress it: reducing autoreactive inflammatory signaling while preserving or enhancing other immune surveillance functions. The OGF pathway in particular is thought to restore immune regulatory balance rather than simply turn the immune system down.

Evidence by Condition

Crohn's Disease: Strongest Clinical Evidence

The most robust human trial data for LDN comes from Crohn's disease research led by Jill Smith and colleagues at Penn State.

Smith et al. 2011 (Digestive Diseases and Sciences): Phase 2 open-label trial in pediatric Crohn's patients (ages 8-18) with active disease. Fourteen patients received LDN 0.1mg/kg/day for 8 weeks. Results:

• 88% response rate (PCDAI reduction ≥12.5 points)
• 33% achieved remission (PCDAI ≤10)
• Endoscopic improvement documented in responders
• No significant adverse effects; the side effect profile was better than placebo-comparable

The pediatric data was particularly striking because Crohn's in children is often more aggressive than adult-onset disease, and these patients had failed or been unable to tolerate standard therapies.

Adult extension data confirmed similar patterns: response rates in the 40-75% range in adult Crohn's patients, with clinical remission achievable in a meaningful subset. Multiple case series from gastroenterology practices in the UK, US, and Norway have documented consistent results.

The Crohn's mechanism is particularly coherent: LDN's TLR4 blockade reduces the gut inflammatory cascade driven by bacterial translocation (relevant given the mucosal barrier dysfunction in IBD), while the OGF pathway modulation reduces autoreactive T cell proliferation in the intestinal mucosa.

Evidence grade: B. Phase 2 trials show consistent positive results. An adequately powered Phase 3 RCT has not been completed, which limits this to Grade B despite the consistency of the findings.

Fibromyalgia: Best Controlled Trial Evidence

Fibromyalgia, while not strictly autoimmune, shares neuroinflammatory mechanisms relevant to the autoimmune context.

Younger & Mackey (2009) pilot: 10 women with fibromyalgia received LDN 4.5mg nightly in a crossover trial against placebo. Significant pain reduction (30% below baseline) during LDN treatment, with reversal during placebo washout. The crossover design provided robust internal control.

Younger et al. (2013) full RCT: 31 women with fibromyalgia in a double-blind, crossover design (12 weeks LDN, 12 weeks placebo, with washout). Results:

• Significant pain reduction during LDN compared to placebo (p<0.05)
• Reduced inflammatory markers (specifically, monocyte-derived cytokines IL-12p70 and TNF-α were significantly lower during LDN treatment)
• Improved mood and life satisfaction during LDN periods
• Mechanistic finding: LDN's anti-inflammatory effect was measurable in peripheral blood, not just subjectively reported

The fibromyalgia evidence is the most methodologically rigorous LDN autoimmune trial completed to date, and the inflammatory marker data provides biological evidence for the TLR4 mechanism in human subjects.

Evidence grade: B. Single crossover RCT with consistent pilot data.

Multiple Sclerosis

Cree et al. (2010) Phase 1 trial: 40 patients with primary progressive MS received LDN 4.5mg daily for 8 weeks. Primary endpoint was safety and tolerability, both confirmed. Secondary endpoints showed trends toward reduced spasticity and improved quality of life, with one mental health sub-scale reaching statistical significance.

The MS evidence base has grown substantially since 2010 through patient registry data and multiple small trials. The LDN Research Trust maintains a comprehensive registry of patient-reported outcomes in MS, with thousands of participants reporting symptom improvements.

The mechanism is coherent for MS: TLR4 is upregulated in MS lesions; microglial activation via TLR4 is implicated in demyelination pathology. OGF pathway modulation may reduce autoreactive T cell attacks on myelin.

Evidence grade: B. Phase 1 safety trial with positive secondary signals; larger trials are ongoing but not completed.

Hashimoto's Thyroiditis

The evidence specifically for LDN in Hashimoto's is more limited than for Crohn's or fibromyalgia. There are no completed RCTs targeting Hashimoto's as the primary endpoint. What exists:

• Bernard Bihari's clinical observations: improved thyroid function and antibody burden in Hashimoto's patients taking LDN (unpublished case series)
• Patient registry data from LDN Research Trust: consistently positive patient-reported outcomes in autoimmune thyroiditis
• Mechanistic rationale: TLR4 activation has been documented in thyroid tissue from Hashimoto's patients; TLR4 drives NF-κB → IL-6, IL-17, TNF-α (the cytokines that perpetuate lymphocytic infiltration and thyrocyte destruction)
• OGF pathway relevance: regulatory T cell (Treg) deficiency is well-documented in Hashimoto's; OGF pathway enhancement may support Treg expansion

Evidence grade: C for Hashimoto's specifically. Compelling mechanistic rationale and consistent patient reports, but no controlled trial data specifically for thyroid autoimmunity.

For the Hashimoto's-specific deep dive (TLR4 overexpression in thyroid tissue, who is the right candidate, detailed monitoring protocol, and how to get a prescription specifically for Hashimoto's), see the LDN for Hashimoto's guide.

The Hashimoto's natural treatment guide places LDN as a Tier 3 advanced option, reserved for patients who have optimized Tier 1 (Vitamin D, Omega-3, Selenium, Magnesium) and Tier 2 (Selenium + Myo-Inositol, diet) interventions without achieving adequate symptom control.

Rheumatoid Arthritis

De Carvalho et al. (2023) published a systematic review of LDN across rheumatological diseases, finding consistent evidence for anti-inflammatory effects relevant to RA, with positive signals in case series and small open-label trials. Preclinical data shows LDN reduces IL-1β and TNF-α production in synovial tissue models.

No completed RCT in RA exists as of early 2026. The LDN Research Trust registry includes substantial RA patient data showing symptom improvement, particularly for pain and morning stiffness.

Evidence grade: C for RA. Mechanistic and preclinical support, registry data, but no clinical trial.

Lupus (SLE)

Case reports and small series document LDN use in mild-to-moderate SLE with symptom improvement (fatigue, pain, cognitive symptoms). The TLR7/TLR9 pathway is more central to lupus pathogenesis than TLR4, which may limit LDN's efficacy relative to Crohn's or fibromyalgia. The OGF pathway benefit may be more relevant in SLE, where lymphocyte dysregulation is a core feature.

Evidence grade: C for SLE. Very limited clinical data, reasonable mechanistic case.

Alopecia Areata

LDN has been used off-label for alopecia areata based on the same TLR4 and immune-modulating rationale. Alopecia areata is a T cell-mediated autoimmune attack on hair follicles, and the OGF pathway's role in reducing autoreactive lymphocyte activity has a coherent mechanistic basis here. Clinical data consists of scattered case reports only.

Evidence grade: C for alopecia areata. No controlled trials; mechanistic rationale only.

Evidence Summary by Condition

LDN is also emerging as one of the most promising interventions for long COVID fatigue and neuroinflammation. For the complete evidence review including the O'Kelly 2022 retrospective study and the ongoing LINCOLN randomized trial, see our LDN for long COVID guide.

The LDN Dosing Protocol

Starting Dose

1.5mg nightly at bedtime.

Some practitioners start even lower (0.5mg or 1.0mg) to minimize initial side effects, particularly vivid dreams. This is especially recommended for patients who are sensitive to medications or who have co-occurring sleep issues. The lower starting dose is not less therapeutic; it simply provides a gentler adaptation period.

Titration Schedule

A standard titration schedule:

Slower titration (increasing by 0.5mg every 4-6 weeks instead of every 4 weeks) is appropriate for patients who experience significant sleep disruption or vivid dreams. There is no evidence that faster titration improves outcomes. Patience during the titration phase generally leads to better long-term tolerability.

Why Bedtime Is Not Optional

The OGF rebound mechanism depends on timing the naltrexone dose to coincide with peak endorphin production at 2:00-4:00 AM. This window is the target.

If LDN is taken in the morning, peak plasma concentration falls in the afternoon, missing the peak endorphin window entirely. You may still get some TLR4 anti-inflammatory benefit (that mechanism is continuous), but the OGF-mediated immune modulation is substantially reduced.

Vivid dreams are a timing signal. If a patient is experiencing vivid or disturbing dreams consistently, it is actually evidence that the drug is hitting the correct window. Endorphin cycling during REM sleep is producing the dream effect. This side effect is not harmful and typically resolves within 2-4 weeks as the system adapts.

Dose Range Discussion

The majority of trials use 4.5mg as the target dose. Some patients, particularly those with chronic pain conditions or neurological symptoms, find doses between 3.0 and 4.5mg optimal. Occasionally patients do better at 2.0-3.0mg and experience increased side effects at 4.5mg without additional benefit.

There is no universal optimal dose. The 4.5mg standard was established empirically and in early trials. Individual titration within the 1.5-4.5mg range is the standard clinical approach.

The Form: Why Compounding Matters

LDN is not commercially available as a pharmaceutical product at these doses. The lowest commercially available naltrexone tablet in the US is 50mg. You cannot cut a 50mg tablet to 1/10th and obtain a consistent or safe dose.

LDN must be compounded. Compounding pharmacies prepare custom-formulated capsules or solutions at the prescribed dose. Most compounding pharmacies are familiar with LDN; it is now one of the more commonly requested compounded preparations in the US.

Forms available:

• Capsules: Most common. 1.5mg, 3.0mg, or 4.5mg capsules filled with the active drug and a neutral filler (lactose or microcrystalline cellulose are standard).
• Liquid solution: Useful for very low starting doses (0.5mg, 1.0mg) or for patients who need gradual dose adjustments without changing capsule strengths. Typically 1mg/mL.

Fillers matter: Naltrexone bioavailability is affected by some fillers. Calcium carbonate as a filler has been reported by some practitioners to slow absorption and reduce efficacy. Request that your compounding pharmacy use lactose or a non-calcium-carbonate filler if you have the choice.

Cost: LDN is inexpensive. A 90-day supply of 4.5mg capsules typically costs $40-80 from most US compounding pharmacies. It is not typically covered by insurance (as an off-label compounded medication), but the out-of-pocket cost is manageable for most patients.

How to Get an LDN Prescription

Which Physicians Can Prescribe

Any licensed physician in the United States can prescribe LDN off-label. The practical challenge is finding a physician familiar enough with the evidence to feel comfortable prescribing an off-label compounded medication.

Most receptive to LDN prescriptions:

• Integrative and functional medicine physicians: most familiar with the literature
• Neurologists (particularly MS specialists): Phase 1 trial data is well-known in this community
• Gastroenterologists (particularly IBD specialists): Smith et al. trials are published in mainstream GI journals
• Rheumatologists: increasingly aware of the LDN evidence base

What to bring to the appointment:

1. A printed summary of the Smith et al. 2011 (Crohn's) or Younger et al. 2013 (fibromyalgia) trial (full papers from PubMed, not summaries)
2. The LDN Research Trust physician information guide (available at ldnresearchtrust.org)
3. A list of your current medications (to confirm no contraindications)
4. A clear articulation of what you've tried, what hasn't worked, and why you're interested in LDN as an adjunct

Telemedicine Options

Several telemedicine platforms now offer LDN consultations with physicians experienced in off-label prescribing. For patients who cannot find a local physician willing to prescribe, this is a legitimate alternative. Ensure the platform operates in your state and uses board-certified physicians.

The LDN Research Trust Physician Directory

The LDN Research Trust (ldnresearchtrust.org) maintains a directory of physicians worldwide who have experience prescribing LDN. This is one of the most reliable resources for finding an LDN-familiar physician in your area.

Questions to Ask Your Doctor

• "I've read the Smith et al. Phase 2 trial on LDN for Crohn's [or Younger et al. for fibromyalgia]. Would you be willing to review the evidence and consider a supervised trial?"
• "LDN is off-label but has a well-established safety profile with no reported serious adverse events in published trials. I understand it's compounded and I've identified a local pharmacy."
• "Given that I'm already on [your current medication], what would you want to monitor if we tried LDN?"

Approaching the conversation as an informed patient seeking a supervised evidence-based trial (rather than demanding a specific medication) is generally more productive.

Safety: What LDN Is and Is Not

Absolute Contraindications

LDN cannot be combined with opioid medications. This includes:

• Prescription opioid pain medications (oxycodone, hydrocodone, morphine, tramadol, codeine, fentanyl)
• Opioid replacement therapies (buprenorphine/Suboxone, methadone)
• Any medication containing opioids

Combining naltrexone (even at low doses) with opioids will block the opioid's effect and, at sufficient opioid levels, may precipitate acute opioid withdrawal. This is a serious, not theoretical, contraindication.

LDN is contraindicated if you are already on full-dose naltrexone (50mg).

Medications Compatible with LDN

• Levothyroxine and other thyroid medications: no pharmacokinetic interaction
• Hydroxychloroquine (Plaquenil): used in lupus/RA, compatible
• Methotrexate: used in RA/psoriasis, compatible
• Biologics (adalimumab, etanercept, ustekinumab, etc.): no documented interaction; LDN has been used alongside biologics
• Azathioprine, mycophenolate: compatible
• Corticosteroids: compatible for short-term use; LDN does not interfere with steroid mechanism
• Most antidepressants (SSRIs, SNRIs): compatible

Side Effects

Common (particularly during first 2-4 weeks):

• Vivid or unusual dreams: the most commonly reported effect. Occurs because LDN disrupts normal opioid receptor cycling during REM sleep. Usually resolves within 2-4 weeks as the body adapts. If persistent and intolerable, reduce dose temporarily or consider taking the dose earlier in the evening.
• Mild sleep disturbance: related to the same mechanism. Some patients find the initial disruption resolves; others find a small dose reduction sufficient.
• Mild nausea: uncommon, usually resolves within first week. Take with a small amount of food if nausea is a concern.

Uncommon:

• Headache in the first week
• Irritability or mood changes (rare)

What LDN does NOT cause:

• Infection risk elevation (unlike biologics and immunosuppressants)
• Liver damage (at these doses, naltrexone hepatotoxicity risk is negligible; it was observed only at 300mg+ doses in obesity trials)
• Dependency or withdrawal symptoms (opioid receptor cycling normalizes rapidly on stopping LDN)

Stopping LDN

LDN can be stopped without tapering. There is no physiological dependency. The opioid receptor system returns to baseline within days of stopping. Some patients report a gradual return of autoimmune symptoms after stopping, consistent with the immune-modulating effect wearing off.

LDN Within a Comprehensive Autoimmune Protocol

LDN is not a standalone treatment. It is a Tier 3 advanced intervention, appropriate when foundational and condition-specific interventions have been optimized.

The AutoimmuneFinder quiz-driven protocol places LDN in the advanced tier for most conditions. Patients are typically directed to LDN consideration after they have:

Tier 1 Foundation (established first):

• Vitamin D3 optimization (VITAL trial: 22% autoimmune incidence reduction)
• Omega-3 EPA+DHA (extensive anti-inflammatory evidence)
• Magnesium glycinate (immune regulation, sleep, inflammation)
• Gut healing (L-glutamine, quality probiotic, digestive enzymes)

Tier 2 Condition-Specific (established second):

• For Hashimoto's: Selenium + Myo-Inositol, gluten elimination, complete supplement strategy (see also the evidence-graded supplement guide across all autoimmune conditions)
• For Crohn's: SCD or Mediterranean diet (PRODUCE trial), curcumin, zinc carnosine
• For RA: High-dose Omega-3, curcumin (Chandran & Goel 2012: equal to diclofenac for RA joint pain), boswellia

LDN fits patients who have done the foundational work and need an additional lever for immune modulation, particularly those with significant inflammatory burden, persistent symptoms on standard treatment, or who wish to minimize immunosuppressive medication.

Key Takeaways

1. LDN works through two distinct mechanisms: TLR4 antagonism (continuous anti-inflammatory) and OGF pathway upregulation (immune modulation via endorphin rebound). Both are well-characterized in preclinical research.

2. Timing is mechanistically essential: LDN must be taken at bedtime to target the 2-4am peak endorphin production window. Morning dosing substantially reduces the OGF mechanism's efficacy.

3. Strongest evidence in Crohn's and fibromyalgia (Grade B: clinical trials). Evidence for Hashimoto's, MS, and RA is Grade C (registry data and mechanistic rationale).

4. Standard protocol: Start 1.5mg nightly, titrate to 4.5mg over 8-12 weeks. Must be compounded by a pharmacy.

5. Absolute contraindication: Any opioid medication (will block opioids and may precipitate withdrawal). Safe with most other autoimmune medications.

6. How to access: Off-label physician prescription → compounding pharmacy. LDN Research Trust physician directory at ldnresearchtrust.org is the best starting resource.

7. Trial duration: Evaluate response at 3 months minimum. LDN is not a rapid-response therapy. Expect gradual improvement over weeks to months.

This article is for educational purposes only and does not constitute medical advice. LDN is an off-label medication that requires physician supervision. Always consult your physician before starting any new medication or supplement, particularly if you take opioid medications or opioid replacement therapy, where LDN is absolutely contraindicated.

Find out whether LDN and other advanced interventions belong in your personalized protocol. Take the free AutoimmuneFinder quiz to see your evidence-graded protocol based on your condition, labs, and symptoms.